MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application

Applicability of an absolute quantitativ

Applicability of an absolute quantitative procedure to monitor intra-individual bcr/abl transcript kinetics in clinical samples from chronic myelogenous leukemia patients

✍ Karl-Anton Kreuzer; Ulrich Lass; Stefan Nagel; Heinz Ellerbrok; Georg Pauli; Bär 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 149 KB

Chimeric bcr/abl fusion proteins are thought to be the molecular 'pathogen' of chronic myelogenous leukaemia (CML). Expression levels of the respective fusion RNAs reflect disease progression as well as remission upon therapeutic intervention in CML patients. However, there is no quick and reliable